echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > "Nature-Medical": One-time use of medicine can inhibit HIV for up to half a year, the "Elite Neutralizing Antibody" Phase 1 trial was published

    "Nature-Medical": One-time use of medicine can inhibit HIV for up to half a year, the "Elite Neutralizing Antibody" Phase 1 trial was published

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    ▎Editor of WuXi AppTec's content team At present, more than 35 million people worldwide are infected with HIV (HIV), and there are nearly 2 million new cases each year.
    AIDS is still one of the major global epidemics

    HIV-1 specific broad-spectrum neutralizing monoclonal antibody targeting HIV-1 envelope protein is one of the therapies under investigation for the treatment and prevention of HIV infection

    HIV-1 is one of the main subtypes of HIV.
    Relatively speaking, HIV-1 has a stronger ability to replicate and has a higher probability of infection and transmission

    One of the antibodies under investigation, named PGT121, was isolated from an African donor infected with HIV-1 subtype A.
    The donor's serum showed excellent broad neutralizing efficacy in the observation cohort, and was therefore regarded as “elite neutralizing”.

    A phase 1 trial recently published by "Nature-Medical" initially showed that PGT121 is safe and shows good antiviral activity in HIV-1 infected persons, and has achieved long-term viral suppression for nearly half a year in individual patients

    Screenshot source: Nature Medicine This research comes from Beth Israel Deaconess Medical Center

    The research team first confirmed the safety and tolerability of the PGT121 antibody in a placebo-controlled trial.
    The subjects included adults who were not infected with HIV, and HIV-infected people who received or did not receive antiretroviral therapy (ART).


    Among the 48 subjects enrolled, no serious adverse events related to treatment, potential immune-mediated diseases, or adverse events of grade 3 or above were reported

    The most common reactions of PGT121 are tenderness, pain and headache at the intravenous injection site

    Next, the research team evaluated antiviral activity in 13 HIV-infected people who did not receive ART therapy

    Due to no medication control, these patients had a detectable viral load at the baseline of the study.
    Among them, 9 had a high viral load (>2000 copies/ml of blood) and 4 had a low viral load (<2000 copies/ml) Blood)

    After a single dose of antibody was injected, among the 9 people with a high baseline viral load, the viral load continued to decline for 7-10 days, and then rebounded to the baseline level on the 28th day

    The viral load of the 4 people with low baseline viral load also decreased.
    Among them, the viral load of 2 people rebounded to the baseline level on the 28th day; but the other 2 people experienced a long-term period of ≥168 days (nearly 6 months) Virus suppression, one of them did not detect viral rebound until day 252, and this was achieved without taking ART drugs

    Dan H.
    Barouch, Director of the BIDMC Virology and Vaccine Research Center, said, “As far as we know, this is reported in the literature.
    After a dose of anti-HIV broad-spectrum neutralizing antibody treatment, the longest period of no ART virus inhibition has been observed.


    "source: 123RF consistent with previous studies of anti-HIV antibody therapy, this trial, the researchers also observed in 13 subjects, 12 people appeared partially resistant to the antibody --HIV The ability of drug therapies and vaccine strategies to quickly develop resistance is one of the reasons the virus is so difficult to eradicate

    However, the researchers also pointed out that the results of the current study indicate that this research antibody may have a higher potency than other single broad-spectrum neutralizing antibodies tested so far

    "All in all, (this) antibody therapy is safe, well tolerated, and has a rapid antiviral effect on HIV-1 infected persons with a detectable viral load

    "The co-first author, Dr.
    Kathryn E.
    Stephenson, BIDMC Virology and Vaccine Research Center, pointed out, "These data indicate that this antibody should be further tested for its ability to maintain the virus's ability to inhibit or block HIV infection, especially with other broad-spectrum neutralizing antibodies.
    The ability to use in combination

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.